Present and future contraception: Does discovery of targets lead to new contraceptives?

Research output: Contribution to journalArticle

Abstract

Although many highly effective methods of reversible contraception are available, high rates of unintended pregnancy and abortion provide evidence that current methods do not meet the needs of all couples. In recent years, a number of highly specific targets have been identified in key pathways that regulate the development of male and female gametes. Support for development of novel approaches has moved from industry to governmental and foundation funders. Continued public funding will be needed to move promising leads into clinical trials.

Original languageEnglish (US)
Pages (from-to)1429-1432
Number of pages4
JournalExpert Opinion on Therapeutic Targets
Volume19
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Contraceptive Agents
Contraception
Induced Abortion
Pregnancy Rate
Germ Cells
Industry
Clinical Trials

Keywords

  • contraception
  • female
  • male
  • targets

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Present and future contraception : Does discovery of targets lead to new contraceptives? / Jensen, Jeffrey.

In: Expert Opinion on Therapeutic Targets, Vol. 19, No. 11, 02.11.2015, p. 1429-1432.

Research output: Contribution to journalArticle

@article{a3db95e36cb648bca8c8e17a7c7cb4b9,
title = "Present and future contraception: Does discovery of targets lead to new contraceptives?",
abstract = "Although many highly effective methods of reversible contraception are available, high rates of unintended pregnancy and abortion provide evidence that current methods do not meet the needs of all couples. In recent years, a number of highly specific targets have been identified in key pathways that regulate the development of male and female gametes. Support for development of novel approaches has moved from industry to governmental and foundation funders. Continued public funding will be needed to move promising leads into clinical trials.",
keywords = "contraception, female, male, targets",
author = "Jeffrey Jensen",
year = "2015",
month = "11",
day = "2",
doi = "10.1517/14728222.2015.1039939",
language = "English (US)",
volume = "19",
pages = "1429--1432",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Present and future contraception

T2 - Does discovery of targets lead to new contraceptives?

AU - Jensen, Jeffrey

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Although many highly effective methods of reversible contraception are available, high rates of unintended pregnancy and abortion provide evidence that current methods do not meet the needs of all couples. In recent years, a number of highly specific targets have been identified in key pathways that regulate the development of male and female gametes. Support for development of novel approaches has moved from industry to governmental and foundation funders. Continued public funding will be needed to move promising leads into clinical trials.

AB - Although many highly effective methods of reversible contraception are available, high rates of unintended pregnancy and abortion provide evidence that current methods do not meet the needs of all couples. In recent years, a number of highly specific targets have been identified in key pathways that regulate the development of male and female gametes. Support for development of novel approaches has moved from industry to governmental and foundation funders. Continued public funding will be needed to move promising leads into clinical trials.

KW - contraception

KW - female

KW - male

KW - targets

UR - http://www.scopus.com/inward/record.url?scp=84946713074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946713074&partnerID=8YFLogxK

U2 - 10.1517/14728222.2015.1039939

DO - 10.1517/14728222.2015.1039939

M3 - Article

C2 - 25910594

AN - SCOPUS:84946713074

VL - 19

SP - 1429

EP - 1432

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 11

ER -